Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

If you are wondering whether CRISPR Therapeutics at around US$48.75 is a bargain or a concern, the key question is how its current share price lines up with what the business may be worth. The stock ...

Lipid nanoparticles, or LNPs, best known as the delivery vehicle for the COVID-19 mRNA vaccines received by billions of people, are now at the center of a much larger medical revolution. Researchers ...

The Society of the Four Arts is collaborating with the Garden Club of Palm Beach for a lecture featuring botanical genetic ...

Co‑injecting three common amino acids with LNPs dramatically boosted both mRNA delivery and CRISPR gene editing efficiency in ...

Barclays 28th Annual Global Healthcare Conference March 12, 2026 8:30 AM EDTCompany ParticipantsAmy Parison - Senior VP ...

Cathie Wood’s ARK Invest added to several beaten-down technology and biotech names while trimming positions elsewhere. The investment manager made a notable purchase in gene-editing company CRISPR ...

Rice University researchers have developed a CRISPR-based gene activation strategy that boosts mitochondrial production in damaged heart cells, improving cardiac function after heart attacks in both ...

CRISPR Therapeutics AG CRSP shares moved lower Tuesday after the biotechnology company outlined plans to raise capital ...

After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...

A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way ...

CRISPR Therapeutics (NasdaqGM:CRSP) has announced a $350 million offering of convertible senior notes. The securities are a form of debt that may convert into equity under certain conditions. The ...